Geneva, Aug. 31 -- International Clinical Trials Registry received information related to the study (NCT07779590) titled 'A Study to Learn About the Outcomes Between Study Medicines, Enzalutamide and Darolutamide Among Men With Metastatic Castration Sensitive Prostate Cancer (mCSPC)' on Aug. 18.
Study Type: Observational
Primary Sponsor: Pfizer
Condition:
Metastatic Castration Sensitive Prostate Cancer (mCSPC)
Intervention:
Drug: darolutamide plus androgen deprivation therapy
Recruitment Status: Not recruiting
Date of First Enrollment: September 1, 2026
Target Sample Size: 4700
To know more, visit https://clinicaltrials.gov/study/NCT07779590
Disclaimer: Curated by HT Syndication....